Stockreport
Gilead Sciences Announces First Quarter 2024 Financial Results
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billionBiktarvy Sales Increased 10% Year-Over-Year to $2.9 billionOncology Sales Increased 18% Year-Over-Year to $789 millionClosed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.“Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Onco
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Forbes Has Listed Gilead as One of America's Best Employers for Diversity [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Maxim Group from $90.00 to $85.00. They now have a "buy" rating on the stock.[MarketBeat]
- Gilead Sciences to Present at Upcoming Investor Conferences[Business Wire]
- Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Barclays PLC from $80.00 to $76.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- More
GILD
SEC Filings
SEC Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website
- More